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Abstract
Background
Available COVID-19 mortality indices are limited to acute inpatient data. Using nationwide
medical administrative data available prior to SARS-CoV-2 infection from the US Veterans
Health Administration (VA), we developed the VA COVID-19 (VACO) 30-day mortality index
and validated the index in two independent, prospective samples.
Methods and findings
We reviewed SARS-CoV-2 testing results within the VA between February 8 and August 18,
2020. The sample was split into a development cohort (test positive between March 2 and
April 15, 2020), an early validation cohort (test positive between April 16 and May 18, 2020),
and a late validation cohort (test positive between May 19 and July 19, 2020). Our logistic
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regression model in the development cohort considered demographics (age, sex, race/eth-
nicity), and pre-existing medical conditions and the Charlson Comorbidity Index (CCI)
derived from ICD-10 diagnosis codes. Weights were fixed to create the VACO Index that
was then validated by comparing area under receiver operating characteristic curves (AUC)
in the early and late validation cohorts and among important validation cohort subgroups
defined by sex, race/ethnicity, and geographic region. We also evaluated calibration curves
and the range of predictions generated within age categories. 13,323 individuals tested pos-
itive for SARS-CoV-2 (median age: 63 years; 91% male; 42% non-Hispanic Black). We
observed 480/3,681 (13%) deaths in development, 253/2,151 (12%) deaths in the early vali-
dation cohort, and 403/7,491 (5%) deaths in the late validation cohort. Age, multimorbidity
described with CCI, and a history of myocardial infarction or peripheral vascular disease
were independently associated with mortality–no other individual comorbid diagnosis
provided additional information. The VACO Index discriminated mortality in development
(AUC = 0.79, 95% CI: 0.77–0.81), and in early (AUC = 0.81 95% CI: 0.78–0.83) and late
(AUC = 0.84, 95% CI: 0.78–0.86) validation. The VACO Index allows personalized esti-
mates of 30-day mortality after COVID-19 infection. For example, among those aged 60–64
years, overall mortality was estimated at 9% (95% CI: 6–11%). The Index further discrimi-
nated risk in this age stratum from 4% (95% CI: 3–7%) to 21% (95% CI: 12–31%), depend-
ing on sex and comorbid disease.
Conclusion
Prior to infection, demographics and comorbid conditions can discriminate COVID-19 mor-
tality risk overall and within age strata. The VACO Index reproducibly identified individuals
at substantial risk of COVID-19 mortality who might consider continuing social distancing,
despite relaxed state and local guidelines.
Introduction
The highly contagious nature of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the lack of widespread immunity, and the absence of an effective vaccine ensure continued
spread of the virus among the general population [1]. As state and local authorities relax guide-
lines, we need accurate and reliable means of identifying those at greatest risk should they
become infected to inform personal choice and public policy.
Several studies have identified risk factors for mortality associated with coronavirus disease
2019 (COVID-19) in the inpatient setting [2–7]. However, these analyses do not adequately
address the issue of identifying at-risk individuals before infection, for several reasons. First,
these analyses were not exclusively based on data present prior to SARS-CoV-2 infection. Sec-
ond, the models require data not routinely available or directly analyzable from administrative
databases or electronic health records (EHR) making them difficult to apply in real time to
large patient populations. Third, a recent systematic review [4] found that most SARS-CoV-2
infection outcome models were based on limited sample sizes, were likely over-fit, and were
not validated in independent data.
The Veterans Health Administration (VA) is the largest integrated health care system in the
United States, providing care at 1,255 health care facilities, including 170 medical centers and
1,074 outpatient sites, serving 6 million Veterans each year. Using data routinely available and
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directly analyzable in the VA national system, we developed the VA COVID-19 (VACO)
Index estimating 30-day COVID-19 mortality after a positive test based on demographics and
pre-existing conditions, and validated its discrimination and calibration. We explored the
VACO Index performance in two different time intervals of the pandemic, and in important
clinical subgroups by sex, race/ethnicity, geographic region, and within age strata.
Methods
Data source and participants
We obtained individual patient data on August 19, 2020 from the VA Corporate Data Ware-
house, which includes daily updates from over 1,200 facilities across the United States. All Vet-
erans who were alive as of January 1, 2020 and active in care (defined as having at least one
clinical encounter between January 1, 2018 and December 31, 2019, with either a recorded
blood pressure or a routine laboratory test result (complete blood count, serum creatinine, ala-
nine transaminase, or aspartate aminotransferase) were eligible. We included patients who
tested positive for SARS-CoV-2 in inpatient or outpatient settings between March 2 and July
18, 2020 and followed them for 30 days.
We identified tested individuals using text searches of laboratory results containing terms
consistent with SARS-CoV-2 or COVID-19. Nearly all tests utilized nasopharyngeal swabs;
<1% were from other sources, serum tests were excluded. Testing was performed in VA, state
public health, and commercial reference laboratories using emergency use authorization
approved SARS-CoV-2 assays. If an individual had more than one test, we used the date of
their first positive test. Baseline was defined as the date of specimen collection unless testing
occurred during hospitalization, in which case it was defined as date of admission. If admission
began more than 14 days prior to testing, possibly indicating nosocomial infection, we set the
baseline to 14 days prior to testing to delineate health status before SARS-CoV-2 infection.
The data were split into a development cohort (positive test between March 2 and April 15,
2020), an early validation cohort (positive test between April 16 and May 18, 2020), and a late vali-
dation cohort (positive test between May 19 and July 19, 2020). Date of last follow-up was August
18, 2020 to allow 30 days of follow-up after testing for all patients. This study was conducted in
compliance with the Health Insurance Portability and Accountability Act (HIPAA) and was
approved by the Institutional Review Boards of VA Connecticut Healthcare System and Yale Uni-
versity, both of whom granted wavers of consent. This cohort study is reported as per the Strength-
ening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (S1 Checklist).
VACO Index development: Candidate predictors
We began by performing a literature review to identify candidate demographic and medical con-
dition predictors available in medical administrative records. Demographic variables included
age, sex (male or female), and race and ethnicity (non-Hispanic Black, non-Hispanic White, His-
panic, or other). Medical conditions included individual components of the Charlson Comorbid-
ity Index (CCI) and the CCI without an age adjustment derived from International Classification
of Diseases, 10th edition (ICD-10) codes [8, 9] present between 730 and 15 days before COVID-
19 testing (S1 Table). Using a previously validated grouping of ICD-10 code-defined comorbidi-
ties recorded during at least one inpatient or two outpatient encounters within the past two years
[10, 11], we also considered conditions reported by other investigators as associated with COVID-
19 mortality that were not included in CCI: asthma and hypertension [12–14].
Deaths were determined using inpatient records and the VA death registry to capture
deaths occurring outside hospitalization. Previous research has demonstrated that these com-
bined sources are as accurate and more up to date than the National Death Index [15].
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Statistical analyses
All data analyses were performed using Stata, version 15.1 (StataCorp, College Station, TX).
We assessed the distribution of variables in the development cohort and their association and
functional forms with 30-day mortality using unadjusted and multivariable logistic regression
models. All variables with P<0.1 in unadjusted models were evaluated for inclusion in the
adjusted models and retained in the final adjusted model for a P<0.05. We double checked the
final multivariable model by reinserting and assessing the significance of previously excluded
individual comorbidity and condition variables–none attained significance at P<0.05. Sex was
included in the final multivariable model, regardless of P-value. CCI values with similar mor-
tality rates were collapsed into five categories (0, 1–3, 4–5, 6–9, 10+). We explored interactions
between variables—there was a significant interaction between age and CCI below the age of
85 that was incorporated into the final model.
Model validation and calibration
We report area under the receiver operating characteristic curves (AUC) and calibration
curves as assessments of the VACO Index performance in development and validation sam-
ples. To validate performance, we froze statistical weights from the final development model,
then generated risk prediction scores for individuals in validation. We used the early and late
validation cohorts, and a combined validation cohort, to evaluate Index performance overall
and in important subgroups: sex (male vs female), race/ethnicity (Black vs non-Black), and
VA-defined geographic regions combined to generate two approximately equal population
samples (Northeast and West vs Southeast and Midwest). We assessed Index calibration with
the Hosmer-Lemeshow goodness-of-fit test in the development cohort, and with plots of
observed versus predicted 30-day mortality in 10 strata containing equal numbers of deaths, in
development and validation cohorts and in validation cohort subgroups by sex, race/ethnicity,
and geographic region. We also compared the range of predicted mortality values stratified by
age category.
Results
Participants
Among tests performed from February 8 to July 19, 2020, we identified 13,323 individuals test-
ing positive for SARS-CoV-2 in the VA who met our inclusion criteria. The first VA positive
test was on March 2, 2020. Based on date of their first positive test, we assigned 3,681 patients
to the development cohort, 2,151 patients to the early validation cohort, and 7,491 patients to
the late validation cohort (Fig 1). As of August 18, 2020, we observed 1,136 deaths (9%): 480
(13%) in the development cohort, 253 (12%) in the early validation cohort, and 403 (5%) in the
late validation cohort. The development cohort was older (median age: 64.8 vs 62.3), with a
higher proportion of non-Hispanic Blacks (52% vs 38%), and a lower proportion of males
(93% vs 90%) than the combined validation cohorts (Table 1). The development cohort had
fewer patients with a Charlson Comorbidity Index of zero indicating absence of comorbid dis-
ease (26% vs 35%).
VACO Index development
Univariate analyses demonstrated strong associations between multiple candidate predictors
and 30-day mortality in the development cohort (Table 2). The strongest predictor was age,
with mortality ranging from 0.3% among those under age 50 to 44% among those 90 or more
years of age. Women experienced lower mortality than men. Before adjustment, non-Hispanic
PLOS ONE 30-day COVID-19 mortality index based on pre-existing data
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White patients had higher mortality, although these differences vanished after adjustment with
age and CCI. Many pre-existing conditions were associated with mortality including prior
myocardial infarction (MI), chronic kidney disease (CKD), chronic lung disease, diabetes with
complications, hypertension, and peripheral vascular disease (PVD), both individually and
combined in the CCI.
VACO Index specification and performance
Age alone was strongly associated with mortality (Table 2) with an AUC of 0.77 (95% CI:
0.75–0.79). There was a significant interaction between CCI and age below the age of 85. Dis-
crimination improved in the multivariable model after supplementing age with sex, CCI, and
MI or PVD (AUC: 0.79, 95% CI: 0.77–0.81; Fig 2). When we applied the VACO Index to the
validation cohorts, it maintained good discrimination in the early (AUC: 0.81, 95% CI: 0.78–
0.83) and late (AUC: 0.84, 95% CI: 0.78–0.86) validation cohorts. The AUCs for important
Fig 1. Flow diagram of VACO Index cohort selection. Flow diagram showing selection of VACO Index cohorts from
5,834,543 patients active in VA care as of January 1, 2020. All COVID-19 tests were performed in the VA. Patients with
COVID-19 tests after July 18, 2020 did not have 30 days of follow-up and were excluded from the analysis.
https://doi.org/10.1371/journal.pone.0241825.g001
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Table 1. Characteristics of patients in VACO Index development and validation cohorts.
Cohort
Combined Development &
Validation
Development Validation, Early Validation, Late Validation,
Combined
P value�
Testing dates 3/2/2020–7/18/2020 3/2/2020–4/15/
2020
4/16/2020–5/18/
2020
5/19/2020–7/18/
2020
4/16/2020–7/18/2020
N 13,323 3,681 2,151 7,491 9,642
30-day Deaths, n (%) 1,136 (8.5) 480 (13.0) 253 (11.8) 403 (5.4) 656 (6.8)
Age, median (IQR) 63.1 (50.0–72.8) 64.8 (53.7–73.4) 67.6 (57.5–75.0) 60.6 (46.0–71.7) 62.3 (48.8–72.5) <0.001
Categories, N (%)
20–49 3,326 (25.0) 717 (19.5) 324 (15.1) 2,285 (30.5) 2,609 (27.1) <0.001
50–54 1,072 (8.0) 279 (7.6) 130 (6.0) 663 (8.9) 793 (8.2)
55–59 1,292 (9.7) 375 (10.2) 204 (9.5) 713 (9.5) 917 (9.5)
60–64 1,598 (12.0) 481 (13.1) 282 (13.1) 835 (11.1) 1,117 (11.6)
65–69 1,472 (11.0) 433 (11.8) 256 (11.9) 783 (10.5) 1,039 (10.8)
70–74 2,119 (15.9) 654 (17.8) 415 (19.3) 1,050 (14.0) 1,465 (15.2)
75–79 1,004 (7.5) 293 (8.0) 200 (9.3) 511 (6.8) 711 (7.4)
80–89 1,043 (7.8) 326 (8.9) 237 (11.0) 480 (6.4) 717 (7.4)
�90 397 (3.0) 123 (3.3) 103 (4.8) 171 (2.3) 274 (2.8)
Race/Ethnicity
Non-Hispanic White 5,148 (38.6) 1,194 (32.4) 934 (43.4) 3,020 (40.3) 3,954 (41.0) <0.001
Non-Hispanic Black 5,589 (42.0) 1,896 (51.5) 892 (41.5) 2,801 (37.4) 3,693 (38.3)
Hispanic 1,734 (13.0) 405 (11.0) 203 (9.4) 1,126 (15.0) 1,329 (13.8)
Other/Unknown 852 (6.4) 186 (5.1) 122 (5.7) 544 (7.3) 666 (6.9)
Male sex 12,114 (90.9) 3,410 (92.6) 1,993 (92.7) 6,711 (89.6) 8,704 (90.3) <0.001
Comorbidity
Asthma 663 (5.0) 237 (6.4) 89 (4.1) 337 (4.5) 426 (4.4) <0.001
Hypertension 7,825 (58.7) 2,321 (63.1) 1,424 (66.2) 4,080 (54.5) 5,504 (57.1) <0.001
Charlson Comorbidities
AIDS 223 (1.7) 76 (2.1) 36 (1.7) 111 (1.5) 147 (1.5) 0.033
Cancer 1,585 (11.9) 505 (13.7) 288 (13.4) 792 (10.6) 1,080 (11.2) <0.001
Cancer, metastatic 228 (1.7) 73 (2.0) 45 (2.1) 110 (1.5) 155 (1.6) 0.141
Cerebrovascular accident 1,578 (11.8) 484 (13.1) 370 (17.2) 724 (9.7) 1,094 (11.3) 0.004
Chronic pulmonary
disease
3,022 (22.7) 956 (26.0) 541 (25.2) 1,525 (20.4) 2,066 (21.4) <0.001
Congestive heart failure 1,857 (13.9) 587 (15.9) 396 (18.4) 874 (11.7) 1,270 (13.2) <0.001
Diabetes 4,900 (36.8) 1,485 (40.3) 874 (40.6) 2,541 (33.9) 3,415 (35.4) <0.001
Diabetes with
complications
2,813 (21.1) 884 (24.0) 544 (25.3) 1,385 (18.5) 1,929 (20.0) <0.001
Dementia 1,337 (10.0) 434 (11.8) 368 (17.1) 535 (7.1) 903 (9.4) <0.001
Liver disease, mild 1,387 (10.4) 429 (11.7) 274 (12.7) 684 (9.1) 958 (9.9) 0.004
Liver disease, severe 140 (1.1) 36 (1.0) 30 (1.4) 74 (1.0) 104 (1.1) 0.608
Myocardial infarction 742 (5.6) 219 (5.9) 172 (8.0) 351 (4.7) 523 (5.4) 0.240
Peptic ulcer disease 218 (1.6) 64 (1.7) 47 (2.2) 107 (1.4) 154 (1.6) 0.567
Peripheral vascular disease 1,800 (13.5) 572 (15.5) 385 (17.9) 843 (11.3) 1,228 (12.7) <0.001
Plegia 276 (2.1) 69 (1.9) 81 (3.8) 126 (1.7) 207 (2.1) 0.319
Renal disease 2,365 (17.8) 770 (20.9) 459 (21.3) 1,136 (15.2) 1,595 (16.5) <0.001
Rheumatologic disease 243 (1.8) 79 (2.1) 38 (1.8) 126 (1.7) 164 (1.7) 0.001
Charlson Comorbidity Index
0 4,321 (32.4) 970 (26.4) 527 (24.5) 2,824 (37.7) 3,351 (34.8) <0.001
(Continued)
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subgroups in the early, late, and combined validation cohorts suggested good model discrimi-
nation in men vs women, Black vs non-Black individuals, and between those living in VA
Northeast and West regions vs the Southeast and Midwest regions (Table 3).
Calibration and discrimination of the VACO Index beyond age alone
Hosmer-Lemeshow goodness-of-fit testing supported good calibration of the index in devel-
opment (P = 0.847, indicating no significant lack of fit). Calibration curves of predicted versus
observed 30-day mortality illustrated good calibration of the VACO Index in development,
with modest overestimation of mortality in the early and late validation cohorts in which over-
all observed mortality rates progressively decreased (Fig 3). The VACO index demonstrated
stable performance between the development and combined validation cohorts across sex,
race/ethnicity, and geographic region subgroups (Fig 4).
The VACO Index can be used to estimate COVID-19 30-day mortality risk by age strata
and covariates (Fig 5; S1 File). For example, among males 60–64 years of age, overall mortality
was estimated as 9% (95% CI: 6–11%). The VACO Index provided risk estimates ranging from
5% (95% CI: 3–7%) for men with a CCI of zero indicating no comorbidity, to 22% (95% CI:
12–31%) for men with a CCI of 10 or more and a history of MI or PVD. Similar trends were
seen across other age strata.
Discussion
Using information present prior to SARS-CoV-2 infection from a national healthcare system,
we created and validated in two prospective, independent samples a practical index that can
predict 30-day COVID-19 mortality. The VACO Index is based on real world data, routinely
available in medical administrative datasets. Our findings describe the experience of a large,
racially and ethnically diverse, fully integrated healthcare system, encompassing inpatient and
outpatient care. Discrimination of the VACO Index was maintained in both validation sam-
ples, and despite major changes in overall observed mortality over time, the Index only mod-
estly overestimated mortality in the validation samples. The VACO Index identifies
individuals at greatest risk for COVID-19 mortality, enabling patients, providers, healthcare
systems, insurers, and accountable care organizations to make better informed decisions.
We are one of the first groups to use pre-existing information and multivariable modeling
to generate a mortality risk index, and our findings are likely more generalizable than earlier
studies [16]. Our sample was larger than most prior studies and we included patients testing
positive for SARS-CoV-2 in both inpatient and outpatient settings. Most importantly, discrim-
ination and calibration of the VACO index validated well for two different time periods in the
Table 1. (Continued)
Cohort
Combined Development &
Validation
Development Validation, Early Validation, Late Validation,
Combined
P value�
1–3 5,521 (41.4) 1,597 (43.4) 900 (41.8) 3,024 (40.4) 3,924 (40.7)
4–5 1,661 (12.5) 517 (14.0) 336 (15.6) 808 (10.8) 1,144 (11.9)
6–9 1,562 (11.7) 502 (13.6) 330 (15.3) 730 (9.7) 1,060 (11.0)
�10 258 (1.9) 95 (2.6) 58 (2.7) 105 (1.4) 163 (1.7)
�� Development vs Combined validation cohorts
Abbreviations: IQR = interquartile range, AIDS = acquired immunodeficiency syndrome
https://doi.org/10.1371/journal.pone.0241825.t001
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Table 2. VACO Index development cohort unadjusted associations with 30-day mortality (n = 3,681; 480 deaths).
Odds Ratio 95% CI P-value
Demographics
Age, in years
20–49 0.08 (0.02–0.39) 0.002
50–54 Reference - -
55–59 1.60 (0.71–3.59) 0.254
60–64 2.95 (1.41–6.14) 0.004
65–69 4.83 (2.35–9.89) <0.001
70–74 7.02 (3.51–14.03) <0.001
75–79 8.22 (4.00–16.89) <0.001
80–89 14.45 (7.15–29.21) <0.001
�90 23.48 (11.05–49.88) <0.001
Race/Ethnicity
Non-Hispanic White Reference - -
Non-Hispanic Black 0.71 (0.58–0.88) 0.001
Hispanic 0.58 (0.41–0.84) 0.003
Other/Unknown 0.52 (0.31–0.88) 0.015
Male sex 4.67 (2.38–9.13) <0.001
Comorbidity
Asthma 0.85 (0.56–1.28) 0.437
Hypertension 2.65 (2.09–3.35) <0.001
Charlson Comorbidities
AIDS 1.13 (0.59–2.16) 0.708
Cancer 1.63 (1.27–2.09) <0.001
Cancer, metastatic 1.46 (0.79–2.68) 0.224
Cerebrovascular accident 1.96 (1.54–2.50) <0.001
Chronic pulmonary disease 1.53 (1.24–1.88) <0.001
Congestive heart failure 2.32 (1.86–2.90) <0.001
Diabetes 1.73 (1.43–2.10) <0.001
Diabetes with complications 2.02 (1.64–2.47) <0.001
Dementia 3.25 (2.57–4.11) <0.001
Liver disease, mild 0.82 (0.60–1.13) 0.226
Liver disease, severe 3.39 (1.69–6.83) 0.001
Myocardial infarction 2.33 (1.69–3.22) <0.001
Peptic ulcer disease 1.55 (0.82–2.93) 0.175
Peripheral vascular disease 2.74 (2.20–3.42) <0.001
Plegia 1.00 (0.49–2.03) 0.999
Renal Disease 2.51 (2.04–3.09) <0.001
Rheumatologic disease 1.86 (1.08–3.21) 0.026
Charlson Comorbidity Index
0 Reference - -
1–3 3.91 (2.71–5.65) <0.001
4–5 6.33 (4.23–9.46) <0.001
6–9 8.12 (5.46–12.06) <0.001
�10 9.54 (5.41–16.83) <0.001
Charlson Comorbidity Index and Age Interaction Term
Age <85
(Continued)
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pandemic, and among important subgroups including men and women, racial/ethnic minori-
ties, and those living in different geographic regions of the US.
The strong relationship between age and COVID-19 mortality has been a consistent finding
across multiple studies [17–19] and age was the strongest predictor in both unadjusted and
adjusted analyses. The VACO Index allows personalized estimates of 30-day mortality after
COVID-19 infection stratified by age. For example, among those aged 60–64 years, overall
mortality was estimated at 9% (95% CI: 6–11%). The Index further discriminated risk in this
Table 2. (Continued)
Odds Ratio 95% CI P-value
Charlson Comorbidity Index
0 Reference - -
1–3 3.77 (2.48–5.73) <0.001
4–5 7.12 (4.52–11.21) <0.001
6–9 8.63 (5.51–13.52) <0.001
�10 13.65 (7.49–24.90) <0.001
Age 85+, any Charlson Comorbidity Index value 25.38 (16.17–39.82) <0.001
Abbreviations: CI = confidence interval, IQR = interquartile range, AIDS = acquired immunodeficiency syndrome
https://doi.org/10.1371/journal.pone.0241825.t002
Fig 2. Forest plot of VACO Index 30-day mortality multivariable model. Forest plot of odds ratios (OR) and 95%
confidence intervals (CI) of VACO Index variables from multivariable logistic regression model derived from
development cohort (n = 3,681). Abbreviations: MI or PVD = history of myocardial infarction or peripheral vascular
disease.
https://doi.org/10.1371/journal.pone.0241825.g002
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age stratum from 4% (95% CI: 3–7%) to 21% (95% CI: 12–31%), depending on sex and comor-
bid disease. This added discrimination is particularly relevant for patients age 60–74 who are
both at substantial risk and often remain employed. Thirty-nine percent of those age 60–74 in
the US are employed [20], thus accurate personalized risk estimation can better inform per-
sonal and system level decisions regarding returning to work or other group settings.
Most prior studies considered only individual comorbid conditions such as asthma, chronic
lung disease, diabetes, hypertension, and vascular disease [6, 7, 12, 21–23]. Liang et al. found
that comorbidity count predicted critical illness in hospitalized patients in China [3]. We
found that multimorbidity captured by the CCI has a stronger relationship with mortality than
nearly all individual comorbid conditions. After adjustment using the CCI, only a prior MI or
PVD was independently associated with mortality. CCI also has the advantage of straightfor-
ward calculation from ICD-10 diagnosis codes obtained from medical administrative data,
and is widely used across numerous diseases, health care systems, and populations [9]. Our
finding that MI and PVD added independent prognostic information underscores the likely
importance of thrombotic complications in COVID-19 [24, 25]. It stands to reason that those
with pre-existing vascular disease are more susceptible to thrombosis if infected.
The most important limitation of the VACO Index is that it was developed on patients who
presented for COVID-19 testing early in the pandemic, presumably because they had symp-
tomatic disease. COVID-19 testing capacity in the US was limited early in the pandemic, and
testing was reserved for patients with significant symptoms that might represent a more severe
infection. While the discrimination of the VACO Index was maintained in both prospective
independent validations, index predictions modestly over-estimated mortality risk in valida-
tion, particularly in the late validation cohort. Mortality rates among those testing positive for
COVID-19 are decreasing as US testing capacity improves, permitting testing of more mildly
symptomatic and asymptomatic people who are less likely to succumb to the disease. Overall
mortality rate in our development cohort was nearly three times that found in our most recent
Table 3. Validation of VACO Index 30-day COVID-19 mortality estimates using area under the receiver operating characteristic curves.
Cohort
Development Validation, Early Validation, Late Validation, Combined
Testing Dates 3/2/2020–4/15/2020 4/16/2020–5/18/2020 5/19/2020–7/18/2020 4/16/2020–7/18/2020
N 3,681 2,151 7,491 9,642
30-day Deaths, n (%) 480 (13.0) 253 (11.8) 403 (5.4) 656 (6.8)
Model, AUC (95% CI)
Age 0.77 (0.75–0.79) 0.80 (0.77–0.82) 0.83 (0.81–0.84) 0.82 (0.81–0.84)
Charlson 0.73 (0.71–0.75) 0.75 (0.72–0.78) 0.78 (0.76–0.80) 0.78 (0.76–0.80)
Index 0.79 (0.77–0.81) 0.81 (0.78–0.83) 0.84 (0.78–0.86) 0.84 (0.82–0.85)
Index Validation in Subgroups, AUC (95% CI)
Sex
Male n/a 0.80 (0.71–0.83) 0.83 (0.81–0.84) 0.83 (0.81–0.84)
Female n/a 0.79 (0.58–1.00) 0.91 (0.82–0.99) 0.87 (0.76–0.97)
Race/Ethnicity
Black n/a 0.79 (0.74–0.82) 0.81 (0.78–0.84) 0.81 (0.79–0.84)
Other n/a 0.81 (0.78–0.84) 0.84 (0.83–0.86) 0.85 (0.83–0.86)
Geographic region
Northeast & West n/a 0.81 (0.78–0.85) 0.82 (0.80–0.86) 0.84 (0.81–0.86)
Midwest & Southeast n/a 0.79 (0.74–0.83) 0.84 (0.83–0.86) 0.83 (0.82–0.84)
Abbreviations: AUC = Area under receiver operating characteristic curse, CI = confidence interval
https://doi.org/10.1371/journal.pone.0241825.t003
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validation cohort (13% vs 5%). Predictive indices developed in the context of high mortality
rates will almost inevitably overestimate risk in samples with substantially lower mortality.
However, if discrimination of the index is preserved, it is possible to adjust calibration as rates
eventually stabilize.
COVID-19 testing criteria and rates, test positivity rates, and mortality are evolving with
the pandemic. Centers for Disease Control and Prevention (CDC) data estimate that the num-
ber of people with antibody evidence of SARS-CoV-2 infection is many times the number of
reported COVID-19 test-positive cases [26]. The CDC report did not stratify their results by
age, and older people are almost certainly more likely to experience symptoms if infected.
While the CDC report suggested that the overall ratio of asymptomatic to symptomatic infec-
tions was ~10:1, it may be substantially lower for older individuals. Future research should
Fig 3. Calibration plots of VACO Index: Development, early validation, late validation, and combined validation
cohorts. Calibration plots of VACO Index predicted 30-day mortality risk versus observed patient mortality across the
cohorts. Error bars show 95% confidence intervals and dashed lines indicate perfect agreement between predicted
versus observed patient mortality. a. Development cohort: test positive between March 2 and April 15, 2020, n = 3,681,
480 deaths. b. Early validation cohort: test positive between April 16 and May 18, 2020, n = 2,151, 253 deaths. c. Late
validation cohort: test positive between May 19 and July 18, 2020, n = 7,491, 403 deaths. d. Combined early and late
validation cohorts: test positive between April 16 and July 18, 2020, n = 9,642, 656 deaths.
https://doi.org/10.1371/journal.pone.0241825.g003
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Fig 4. Calibration plots of VACO Index: Combined cohort subgroups. Calibration plots of VACO Index 30-day
predicted mortality risk versus observed patient mortality. Error bars show 95% confidence intervals and dashed lines
indicate perfect agreement between predicted versus observed patient mortality. Development cohort: test positive
between March 2 and April 15, 2020, n = 3,681, 480 deaths. Combined early and late validation cohorts: test positive
between April 16 and July 18, 2020, n = 9,642, 656 deaths. Subgroups: Men vs women; Black vs non-Black race;
Northeast (NE) + West (W) regions vs Southeast (SE) + Midwest (MW) regions.
https://doi.org/10.1371/journal.pone.0241825.g004
Fig 5. Range of 30-day mortality predictions from age alone and VACO Index. Bar graphs demonstrating the additional variation in
mortality prediction provided by the VACO Index over age alone across age categories in the combined validation cohort (n = 9,642). The
diamonds indicate predicted 30-day mortality within each age category when only age is used to generate the predicted value. The bars
show the range of predicted 30-day mortality within the same age category provided by the VACO Index, where age is supplemented with
sex and comorbidities.
https://doi.org/10.1371/journal.pone.0241825.g005
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examine this ratio stratified by age as a potential factor in mortality risk estimation. We are
gathering data to adjust risk estimates based on the ratio of asymptomatic to symptomatic
infections stratified by age; however, this is beyond the scope of this analysis.
This study has other limitations. Our study population was limited to Veterans in VA care.
Prior work has demonstrated that while Veterans in VA care are older and have a higher prev-
alence of chronic health conditions and risk behaviors than the general US population [27–
29], after adjusting for age, sex, race/ethnicity, region, and residence location, there are no sig-
nificant differences in total disease burden [29]. VA has excellent mortality assessment [15],
but delays in registering outpatient deaths could result in some under reporting. We only
included Veterans receiving COVID-19 testing in the VA—others may have been tested and
treated outside the VA. In the future, when Center for Medicare and Medicaid Services (CMS)
data are available, this limitation could be addressed in Veterans age 65 and older. Our goal
was to create a predictive model using pre-existing data that is available and readily analyzable
in real time in most medical administrative data. Consequently, we did not consider laboratory
data, vital signs, medications, or information typically residing in text notes, such as symp-
toms, physical exam findings, or imaging. We have demonstrated internal generalizability of
the VACO Index within the VA—we recommend further validation in external datasets before
applying the VACO Index outside of the VA.
In summary, using data from a national healthcare system, we developed and validated the
VACO Index, a short-term mortality risk index based upon directly analyzable data available
prior to infection with SARS-CoV-2. By doing so, we provide timely, quantifiable, and individ-
ualized risk estimates that successfully differentiate risk of 30-day mortality among those of
similar age to better inform personal decision making and public policy as countries begin to
relax lockdown guidelines.
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